Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium

Cancer Treatment Reviews

Volumn 34, Issue 4, 2008, Pages 328-338

  Vaughn, David J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bladder cancer; Cisplatin ineligible; Platinum ineligible; Transitional cell carcinoma; Urothelial carcinoma

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FOLIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; VINBLASTINE; VINFLUNINE; VORINOSTAT;

ADD ON THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; BLADDER CARCINOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DRUG MEGADOSE; DRUG USE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEART FUNCTION; HUMAN; KARNOFSKY PERFORMANCE STATUS; KIDNEY FUNCTION; LEUKOPENIA; LUNG TOXICITY; LYMPHOCYTOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERIPHERAL NEUROPATHY; REVIEW; SEPSIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; UROTHELIUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMORBIDITY; HUMANS; PLATINUM COMPOUNDS; URINARY BLADDER NEOPLASMS;

EID: 43949118117     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.12.006     Document Type: Review

References (63)

1. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
2. NCCN. Bladder cancer treatment guidelines 2005. National Comprehensive Cancer Network; 2005.
3. Vaughn D.J., and Malkowicz S.B. Recent advances in bladder cancer chemotherapy. Cancer Invest 19 (2001) 77-85
4. Loehrer Sr. P.J., Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10 (1992) 1066-1073
5. Troner M., Birch R., Omura G.A., et al. Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. J Urol 137 (1987) 660-662
6. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (1997) 2564-2569
7. Sternberg C.N., Yagoda A., Scher H.I., et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139 (1988) 461-469
8. Sternberg C.N., De Mulder P.H., Schornagel J.H., et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
9. Sternberg C.N., De M.P., Schornagel J.H., et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006) 50-54
10. Lorusso V., Manzione L., De V.F., et al. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164 (2000) 53-56
11. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000) 3068-3077
12. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
13. Dreicer R., Manola J., Roth B.J., et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 18 (2000) 1058-1061
14. Sengelov L., Kamby C., Lund B., et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 16 (1998) 3392-3397
15. Srinivas S., and Colocci N. Nonplatinum therapy in advanced bladder cancer. Expert Rev Anticancer Ther 6 (2006) 887-894
16. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107 (2006) 506-513
17. Galsky M., Sonpavde G., and Hutson T.E. Current management of bladder cancer. US Oncol Dis (2006) 62-66
18. Vaughn D.J. Paclitaxel and carboplatin in bladder cancer: recent developments. Eur J Cancer 36 Suppl. 2 (2000) 7-12
19. Bamias A., Tiliakos I., Karali M.D., et al. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol 17 (2006) 553-561
20. Roberts J.T. Chemotherapy for metastatic bladder cancer. Clin Oncol (R Coll Radiol) 17 (2005) 514-523
21. Chester J.D., Hall G.D., Forster M., et al. Systemic chemotherapy for patients with bladder cancer - current controversies and future directions. Cancer Treat Rev 30 (2004) 343-358
22. Sternberg C.N., Donat S.M., Bellmunt J., et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69 (2007) 62-79
23. Ries LA, Melbert D, Krapcho M, Mariotto A, et al. SEER cancer statistics review, 1975-2004; 2007.
24. Pectasides D., Pectasides M., and Economopoulos T. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Cancer Treat Rev 32 (2006) 456-470
25. Linardou H., Aravantinos G., Efstathiou E., et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology 64 (2004) 479-484
26. Vaughn D.J., Malkowicz S.B., Zoltick B., et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 16 (1998) 255-260
27. Bellmunt J., Ribas A., Eres N., et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80 (1997) 1966-1972
28. Carles J., Nogue M., Domenech M., et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 59 (2000) 24-27
29. Bellmunt J., de W.R., Albanell J., et al. A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer. Eur J Cancer 37 (2001) 2212-2215
30. Small E.J., Lew D., Redman B.G., et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 18 (2000) 2537-2544
31. Vaughn D.J., Manola J., Dreicer R., et al. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 95 (2002) 1022-1027
32. Hussain M., Vaishampayan U., Du W., et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
33. Hussain M.H., MacVicar G.R., Petrylak D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 25 (2007) 2218-2224
34. Galsky M.D., Iasonos A., Mironov S., et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 109 (2007) 549-555
35. Galsky M.D. The role of taxanes in the management of bladder cancer. Oncologist 10 (2005) 792-798
36. Garcia J.A., and Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 24 (2006) 5545-5551
37. Roth B.J., Dreicer R., Einhorn L.H., et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12 (1994) 2264-2270
38. Yang M.H., Yen C.C., Chang Y.H., et al. Single agent paclitaxel as a first-line therapy in advanced urothelial carcinoma: its efficacy and safety in patients even with pretreatment renal insufficiency. Jpn J Clin Oncol 30 (2000) 547-552
39. deWit R., Kruit W.H., Stoter G., et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 78 (1998) 1342-1345
40. Dimopoulos M.A., Deliveliotis C., Moulopoulos L.A., et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 52 (1998) 56-60
41. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34 (1998) 1208-1212
42. Kruczynski A., and Hill B.T. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 40 (2001) 159-173
43. Bonfil R.D., Russo D.M., Binda M.M., et al. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 7 (2002) 159-166
44. Bennouna J., Breton J.L., Tourani J.M., et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 94 (2006) 1383-1388
45. Campone M., Cortes-Funes H., Vorobiof D., et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 95 (2006) 1161-1166
46. Olver IN, Byrne MJ, Walpole E, et al. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. Eur J Cancer, in press.
47. Culine S., Theodore C., De Santis M., et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94 (2006) 1395-1401
48. Vaughn DJ, Srinivas S, Stadler W, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). Proc Am Soc Clin Oncol 2007;25:18S [Abstr. 15543].
49. Petrylak D, Vaughn DJ, Srinivas S, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU). In: European cancer conference; 2007 [Abstr.].
50. Barret J.M., Etievant C., and Hill B.T. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 45 (2000) 471-476
51. Paz-Ares L., Bezares S., Tabernero J.M., et al. Review of a promising new agent - pemetrexed disodium. Cancer 97 (2003) 2056-2063
52. Scagliotti G.V., Shin D.M., Kindler H.L., et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21 (2003) 1556-1561
53. Paz-Ares L, Tabernero J, et al. A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder. Proc Am Soc Clin Oncol 1998 [Abstr. 1307].
54. Sweeney C.J., Roth B.J., Kabbinavar F.F., et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24 (2006) 3451-3457
55. Galsky M.D., Mironov S., Iasonos A., et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drug 25 (2007) 265-270
56. Ricci S., Galli L., Chioni A., et al. Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens. Cancer 95 (2002) 1444-1450
57. Turkolmez K., Beduk Y., Baltaci S., et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol 44 (2003) 682-686
58. Ardavanis A., Tryfonopoulos D., Alexopoulos A., et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 92 (2005) 645-650
59. Gitlitz B.J., Baker C., Chapman Y., et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98 (2003) 1863-1869
60. Kaufman D.S., Carducci M.A., Kuzel T.M., et al. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22 (2004) 393-397
61. Li J., Juliar B., Yiannoutsos C., et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 23 (2005) 1185-1191
62. Fechner G., Siener R., Reimann M., et al. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60 (2006) 27-31
63. von der Maase H., Lehmann J., Gravis G., et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 17 (2006) 1533-1538